JPWO2021209356A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021209356A5
JPWO2021209356A5 JP2022562594A JP2022562594A JPWO2021209356A5 JP WO2021209356 A5 JPWO2021209356 A5 JP WO2021209356A5 JP 2022562594 A JP2022562594 A JP 2022562594A JP 2022562594 A JP2022562594 A JP 2022562594A JP WO2021209356 A5 JPWO2021209356 A5 JP WO2021209356A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cancer
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521227A (ja
JP2023521227A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/059376 external-priority patent/WO2021209356A1/en
Publication of JP2023521227A publication Critical patent/JP2023521227A/ja
Publication of JP2023521227A5 publication Critical patent/JP2023521227A5/ja
Publication of JPWO2021209356A5 publication Critical patent/JPWO2021209356A5/ja
Pending legal-status Critical Current

Links

JP2022562594A 2020-04-14 2021-04-12 癌の併用療法 Pending JP2023521227A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063009565P 2020-04-14 2020-04-14
US63/009,565 2020-04-14
US202063110101P 2020-11-05 2020-11-05
US63/110,101 2020-11-05
PCT/EP2021/059376 WO2021209356A1 (en) 2020-04-14 2021-04-12 Combination treatment for cancer

Publications (3)

Publication Number Publication Date
JP2023521227A JP2023521227A (ja) 2023-05-23
JP2023521227A5 JP2023521227A5 (https=) 2024-04-23
JPWO2021209356A5 true JPWO2021209356A5 (https=) 2024-04-23

Family

ID=75497923

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562594A Pending JP2023521227A (ja) 2020-04-14 2021-04-12 癌の併用療法

Country Status (7)

Country Link
US (1) US20230131598A1 (https=)
EP (1) EP4136112A1 (https=)
JP (1) JP2023521227A (https=)
CN (1) CN115397861A (https=)
AU (1) AU2021257570A1 (https=)
CA (1) CA3171597A1 (https=)
WO (1) WO2021209356A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
US20220396623A1 (en) 2021-05-18 2022-12-15 Kymab Limited Uses of anti-icos antibodies
US20250340641A1 (en) 2022-05-18 2025-11-06 Kymab Limited Uses of anti-icos antibodies
WO2024030956A2 (en) * 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
EP2068925A4 (en) 2007-05-07 2011-08-31 Medimmune Llc ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
US8927697B2 (en) 2008-09-12 2015-01-06 Isis Innovation Limited PD-1 specific antibodies and uses thereof
JP5794917B2 (ja) 2008-09-12 2015-10-14 アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ Ｐｄ−１特異抗体およびその使用
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
CN101898945B (zh) 2010-07-27 2013-05-08 大连理工大学 盐析萃取发酵液中丙酮和丁醇的方法
ES2612914T3 (es) 2011-03-31 2017-05-19 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos dirigidos contra Icos y usos de los mismos
EP2892928B1 (en) 2012-09-03 2018-05-30 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies directed against icos for treating graft-versus-host disease
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
TWI719970B (zh) 2015-03-23 2021-03-01 美商永斯醫療股份有限公司 針對ｉｃｏｓ之抗體
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2017321625A1 (en) * 2016-08-30 2019-04-04 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018115859A1 (en) * 2016-12-20 2018-06-28 Kymab Limited Multispecific antibody with combination therapy for immuno-oncology
JP7290568B2 (ja) * 2016-12-20 2023-06-13 カイマブ・リミテッド 癌免疫療法のための併用療法での多重特異性抗体
MX2019008208A (es) 2017-01-09 2019-12-11 Tesaro Inc Métodos para tratar el cáncer con anticuerpos anti-tim-3.
US20200024351A1 (en) * 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
EP3615572A1 (en) * 2017-04-27 2020-03-04 Tesaro Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
JP2020525427A (ja) * 2017-06-21 2020-08-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置するための方法
EP3502140A1 (en) * 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules

Similar Documents

Publication Publication Date Title
JP7122357B2 (ja) がんの治療のための方法、組成物、及びキット
CA3208069A1 (en) Combination therapy with immune cell engaging proteins and immunomodulators
US20050136055A1 (en) CD40 antibody formulation and methods
JP7709434B2 (ja) 抗ｄｌｌ３剤の投与レジメン
KR20220153681A (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
AU2016260895B2 (en) Treatment for multiple myeloma (MM)
WO2017087280A1 (en) Methods of treating her2-positive cancer
JP2023502585A (ja) 癌の治療のための、ＰＤ－１、ＴＧＦβ、及びＴＩＧＩＴの組み合わせ阻害
US20230398229A1 (en) Antibody drug conjugates comprising sting agonists, combinations and methods of use
JP2022184998A (ja) 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ
JP2022535062A (ja) Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療
KR20230093282A (ko) 폐암에 대한 lag-3 길항제 요법
JPWO2021209356A5 (https=)
CN113244386A (zh) 抗pd-1抗体在治疗肿瘤中的用途
JPWO2020113188A5 (https=)
WO2021209358A1 (en) Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein
JPWO2020102770A5 (https=)
CA3212604A1 (en) Methods for treating cancer with anti-ilt3 antibodies
JP2023553257A (ja) がんの組み合わせ治療
US10689459B2 (en) Treatment of breast cancer brain metastases
JPWO2021209357A5 (https=)
TW202436339A (zh) 治療選自非小細胞肺癌或三陰性乳癌的癌症之用途
JP2025524957A (ja) 抗ＧＡＲＰ－ＴＧＦ－β１／ＰＤ－１併用療法
HK40002353B (en) Methods of treating skin cancer by administering a pd-1 inhibitor